Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-7035 in Advanced Solid Tumors With a KRAS G12D Mutation
NCT06619587Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Nov 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 1, open-label trial of GDC-7035 in solid tumor (2 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Adverse Events at 4 years and Percentage of Participants with Dose Limiting Toxicity at 4 years. Started Nov 2024; status: recruiting.
02
Drugs
GDC-7035
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06619587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619587.